Advances in development of hypoallergenic latex immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 5, Issue 6, 2005, Pages 544-551

  Rolland, Jennifer M ^a,b   Drew, Alexander C ^a,b,c   O'Hehir, Robyn E ^a,b,c  

^a Cooperative Research Centre for Asthma ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Hypoallergenic; IgE epitope; Immunotherapy; Latex allergy; T cell epitope peptide

Indexed keywords

ALLERGEN; EPITOPE; IMMUNOGLOBULIN E; LATEX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT DNA; RUBBER; SYNTHETIC PEPTIDE;

ALLERGY; AMINO ACID SUBSTITUTION; ANAPHYLAXIS; ARTICLE; ASTHMA; B LYMPHOCYTE; BASOPHIL; CELL SURFACE; CHEMICAL MODIFICATION; CHILD CARE; CHILD HEALTH; CLINICAL TRIAL; CONFORMATION; CROSS REACTION; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR CLONING; MOLECULAR GENETICS; POLLEN ALLERGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; RISK ASSESSMENT; SENSITIZATION; SEQUENCE HOMOLOGY; SIDE EFFECT; SURFACE PROPERTY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNITED KINGDOM;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HEVEA; HUMANS; IMMUNOTHERAPY; LATEX; LATEX HYPERSENSITIVITY; MUTATION; RECOMBINANT PROTEINS;

EID: 27944493553     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Reunala T, Alenius H, Turjanmaa K, et al. Latex allergy and skin. Curr Opin Allergy Clin Immunol 2004; 4:397-401. A review of the prevalence and outcome of latex allergy in HCWs including trials of specific immunotherapy using unfractionated NRL.
2. Taylor JS, Erkek E. Latex allergy: diagnosis and management. Dermatol Ther 2004; 17:289-301. A comprehensive overview of latex allergy including clinical manifestations, epidemiology and risk factors, diagnosis and preventive measures.
3. Sutherland MF, Suphioglu C, Rolland JM, et al. Latex allergy: towards immunotherapy for health care workers. Clin Exp Allergy 2002; 32:667-673.
4. Taylor JS, Wattanakrai P, Charous BL, et al. Year book focus: latex allergy. In: Theirs BH, Lang PG, editors. 2000 Year book of dermatology and dermatologic surgery. St Louis: Mosby Inc; 1999. pp. 325-368.
5. Condemi JJ. Allergic reactions to natural rubber latex at home, to rubber products, and to cross-reacting foods. J Allergy Clin Immunol 2002; 110 (2 Suppl.):S107-S110.
6. Chiu AM, Kelly KJ. Anaphylaxis: drug allergy, insect stings, and latex. Immunol Allergy Clin North Am 2005; 25:389-405. A clinical perspective on the diagnosis and therapy of anaphylaxis, featuring reactions associated with latex allergy.
7. Latza U, Haamann F, Baur X. Effectiveness of a nationwide interdisciplinary preventive programme for latex allergy. Int Arch Occup Environ Health 2005; 78:394-402.
8. Allmers H, Schmengler J, John SM. Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German health care workers. J Allergy Clin Immunol 2004; 114:347-351. Documentation of the decreased incidence of occupational contact urticaria caused by NRL in HCWs correlating with decreased purchase of powdered NRL gloves in German acute-care hospitals. This study demonstrates the importance of donning powder as a vehicle for eliciting allergic reactions to NRL.
9. Roberts G, Lack G, Northstone K, et al. Prevalence of latex allergy in the community at age 7 years. Clin Exp Allergy 2005; 35:299-300.
10. Brown RH, Hamilton RG, Mintz M, et al. Genetic predisposition to latex allergy: role of interleukin 13 and interleukin 18. Anesthesiology 2005; 102:496-502.
11. Wagner S, Breiteneder H. Hevea brasiliensis latex allergens: current panel and clinical relevance. Int Arch Allergy Immunol 2005; 136:90-97. A useful summary of the current knowledge on the frequency of reactivity to the 13 officially designated allergens of Hevea brasiliensis NRL in different subject groups.
12. Chen YH, Lan JL. Latex allergy and latex-fruit syndrome among medical workers in Taiwan. J Formos Med Assoc 2002; 101:622-626.
13. Ozkan O, Gokdogan F. The prevalence of latex allergy among health care workers in Bolu (Turkey). Dermatol Nurs 2003; 15:543-547; 554.
14. Dudek W, Walusiak J, Wittczak T, et al. Natural rubber latex allergy: antigen specific IgE in Polish blood donors, prevalance and risk factors-preliminary data. Int J Occup Med Environ Health 2005; 18:35-42.
15. Savi E, Maffini I, Burastero SE. A latex-containing hepatitis-B vaccine administered in a severely latex allergic paediatric patient after specific sublingual immunotherapy: a case report. Allergy 2004; 59:1014-1015.
16. Cistero Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Invest Allergol Clin Immunol 2004; 14:17-25.
17. Sastre J, Fernandez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985-994.
18. Pereira C, Pedro E, Tavares B, et al. Specific immunotherapy for severe latex allergy. Allerg Immunol (Paris) 2003; 35:217-225.
19. Leynadier F, Herman D, Vervloet D, et al. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106:585-590.
20. Vozza I, Ranghi G, Quaranta A. Allergy and desensitization to latex. Clinical study on 50 dentistry subjects. Minerva Stomatol 2005; 54:237-245.
21. Banerjee B, Kanitpong K, Fink JN, et al. Unique and shared IgE epitopes of Hev b 1 and Hev b 3 in latex allergy. Mol Immunol 2000; 37:789-798.
22. Raulf-Heimsoth M, Chen Z, Rihs HP, et al. Analysis of T-cell reactive regions and HLA-DR4 binding motifs on the latex allergen Hev b 1 (rubber elongation factor). Clin Exp Allergy 1998; 28:339-348.
23. Wagner S, Radauer C, Hafner C, et al. Characterization of cross-reactive bell pepper allergens involved in the latex-fruit syndrome. Clin Exp Allergy 2004; 34:1739-1746. Molecular characterization of an IgE-reactive bell pepper protein which cross-reacts with Hev b 2, expanding the number of latex allergens known to be involved in the latex-fruit syndrome.
24. Palomares O, Villalba M, Quiralte J, et al. 1,3-beta-glucanases as candidates in latex-pollen-vegetable food cross-reactivity. Clin Exp Allergy 2005; 35:345-351. This study showed that the olive pollen major allergen Ole e 9, a 1,3-β-glucanase, cross-reacts with homologous proteins in birch pollen, tomato, potato, bell-pepper, banana and latex, again implicating Hev b 2 as an allergen responsible for the latex-pollen-fruit/vegetable syndrome.
25. Barrai P, Batanero E, Palomares O, et al. A major allergen from pollen defines a novel family of plant proteins and shows intra- and interspecies cross-reactivity. J Immunol 2004; 172:3644-3651.
26. Bohle B, Wagner B, Vollmann U, et al. Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients. J Immunol 2000; 164:4393-4398.
27. de Silva HD, Sutherland MF, Suphioglu C, et al. Human T-cell epitopes of the latex allergen Hev b 5 in health care workers. J Allergy Clin Immunol 2000; 105:1017-1024.
28. Beezhold DH, Hickey VL, Sussman GL. Mutational analysis of the IgE epitopes in the latex allergen Hev b 5. J Allergy Clin Immunol 2001; 107:1069-1076.
29. de Silva HD, Gardner LM, Drew AC, et al. The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites. Clin Exp Allergy 2004; 34:611-618. Demonstration of dominant T-cell-reactive sites of Hev b 6.01 in the Hev b 6.02 domain using overlapping 20-mer peptides. Dominant T-cell epitope peptides did not bind serum IgE from latex-allergic individuals consistent with candidate hypoallergenic latex preparation for specific immunotherapy.
30. Drew AC, Eusebius NP, Kenins L, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173:5872-5879. Using a strategy of disruption of disulphide bonds, a hypoallergenic recombinant Hev b 6.01 mutant was produced. A synthetic peptide based on the cysteine-substitituted Hev b 6.02 domain of this mutant lacked IgE binding as tested by inhibition ELISA and basophil activation assay but retained T-cell reactivity, consistent with a candidate hypoallergenic preparation.
31. Karisola P, Kotovuori A, Poikonen S, et al. Isolated hevein-like domains, but not 31-kd endochitinases, are responsible for IgE-mediated in vitro and in vivo reactions in latex-fruit syndrome. J Allergy Clin Immunol 2005; 115:598-605. An evaluation of endochitinases from latex, avocado, banana and wheat germ and their corresponding hevein-like domains in causing cross-reactions between latex and fruit allergens. SPT of latex allergic individuals and inhibition ELISA demonstrated the importance of using isolated hevein-like domains rather than the endochitinases in the diagnosis of latex-fruit syndrome.
32. Karisola P, Mikkola J, Kalkkinen N, et al. Construction of hevein (Hev b 6.02) with reduced allergenicity for immunotherapy of latex allergy by comutation of six amino acid residues on the conformational IgE epitopes. J Immunol 2004; 172:2621-2628.
33. Ganglberger E, Radauer C, Wagner S, et al. Hev b 8, the Hevea brasiliensis latex profilin, is a cross-reactive allergen of latex, plant foods and pollen. Int Arch Allergy Immunol 2001; 125:216-227.
34. Wagner S, Breiteneder H, Simon-Nobbe B, et al. Hev b 9, an enolase and a new cross-reactive allergen from hevea latex and molds. Purification, characterization, cloning and expression. Eur J Biochem 2000; 267:7006-7014.
35. Wagner S, Sowka S, Mayer C, et al. Identification of a Hevea brasiliensis latex manganese superoxide dismutase (Hev b 10) as a cross-reactive allergen. Int Arch Allergy Immunol 2001; 125:120-127.
36. Arif SA, Hamilton RG, Yusof F, et al. Isolation and characterization of the early nodule-specific protein homologue (Hev b 13), an allergenic lipolytic esterase from Hevea brasiliensis latex. J Biol Chem 2004; 279:23933-23941. Report on the isolation and purification of a highly allergenic 42 980 Mr latex glycoprotein, Hev b 13, resolving previous controversy on IgE reactivity of the similarly sized Hev b 7. IgE reactivity of Hev b 13 was shown to reside with the carbohydrate moiety, which cross-reacted with a similar component of potato tuber patatin.
37. Yeang HY. Natural rubber latex allergens: new developments. Curr Opin Allergy Clin Immunol 2004; 4:99-104.
38. Pamies R, Oliver F, Raulf-Heimsoth M, et al. No rHev b 12-specific IgE-response in children sensitized to natural rubber latex. Allergy 2005; 60:709-710.
39. Yagami T, Haishima Y, Tsuchiya T, et al. Proteomic analysis of putative latex allergens. Int Arch Allergy Immunol 2004; 135:3-11. A method for the rapid and exhaustive analysis of putative allergens as applied to latex proteins. Non-ammoniated latex proteins were resolved by two-dimensional gel electrophoresis and 50 IgE-reactive proteins (five novel) were analysed by mass spectrometry and database searches.
40. Yeang HY, Cheong KF, Sunderasan E, et al. The 14.6 kd rubber elongation factor (Hev b 1) and 24 kd (Hev b 3) rubber particle proteins are recognized by IgE from patients with spina bifida and latex allergy. J Allergy Clin Immunol 1996; 98:628-639.
41. Sutherland MF, Drew A, Rolland JM, et al. Specific monoclonal antibodies and human immunoglobulin E show that Hev b 5 is an abundant allergen in high protein powdered latex gloves. Clin Exp Allergy 2002; 32:583-589.
42. Mitakakis TZ, Tovey ER, Yates DH, et al. Particulate masks and non-powdered gloves reduce latex allergen inhaled by healthcare workers. Clin Exp Allergy 2002; 32:1166-1169.
43. Yeang HY, Arif SA, Raulf-Heimsoth M, et al. Hev b 5 and Hev b 13 as allergen markers to estimate the allergenic potency of latex gloves. J Allergy Clin Immunol 2004; 114:593-598. The use of a two-site immunoenzymatic assay to analyse the content of six latex allergens in latex gloves. Hev b 5 and Hev b 6.01/6.02 were detected in all gloves tested and the combination of Hev b 5 and Hev b 13 was shown to correlate best with the IgE binding capacity of latex gloves.
44. Beezhold DH, Hickey VL, Sutherland MF, et al. The latex allergen Hev b 5 is an antigen with repetitive murine B-cell epitopes. Int Arch Allergy Immunol 2004; 134:334-340. This study showed that Hev b 5 contains a repetitive linear B-cell epitope, potentially contributing to the high potency of this allergen. Critical residues for IgE binding were identified by site-directed mutagenesis.
45. Reyes-Lopez CA, Hernandez-Santoyo A, Pedraza-Escalona M, et al. Insights into a conformational epitope of Hev b 6.02 (hevein) Biochem Biophys Res Commun 2004; 314:123-130.
46. ••].
47. Branco Ferreira M, Pedro E, Meneses Santos J, et al. Latex and chickpea (Cicer arietinum) allergy: first description of a new association. Allerg Immunol (Paris) 2004; 36:366-371.
48. Fujimura T, Shigeta S, Suwa T, et al. Molecular cloning of a class IV chitinase allergen from Japanese cedar (Cryptomeria japonica) pollen and competitive inhibition of its immunoglobulin E-binding capacity by latex C-serum. Clin Exp Allergy 2005; 35:234-243.
49. Till SJ, Francis JN, Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-1034.
50. Bhalla PL, Singh MB. Engineered allergens for immunotherapy. Curr Opin Allergy Clin Immunol 2004; 4:569-573.
51. Niederberger V, Valenta R. Recombinant allergens for immunotherapy. Where do we stand? Curr Opin Allergy Clin Immunol 2004; 4:549-554.
52. Vrtala S, Focke-Tejkl M, Swoboda I, et al. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 2004; 32:313-320.
53. Cromwell O, Suck R, Kahlert H, et al. Transition of recombinant allergens from bench to clinical application. Methods 2004; 32:300-312.
54. Vrtala S, Hirtenlehner K, Vangelista L, et al. Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. Int Arch Allergy Immunol 1997; 113:246-248.
55. Kussebi F, Karamloo F, Rhyner C, et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 115:323-329.
56. Hantusch B, Krieger S, Untersmayr E, et al. Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library. J Allergy Clin Immunol 2004; 114:1294-1300.
57. Karisola P, Alenius H, Mikkola J, et al. The major conformational IgE-binding epitopes of hevein (Hev b 6.02) are identified by a novel chimera-based allergen epitope mapping strategy. J Biol Chem 2002; 277:22656-22661.
58. Burton MD, Blaher B, Suphioglu C, et al. T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. J Allergy Clin Immunol 1999; 103:255-261.
59. Yagami T, Osuna H, Kouno M, et al. Significance of carbohydrate epitopes in a latex allergen with beta-1,3-glucanase activity., Int Arch Allergy Immunol 2002; 129:27-37.
60. Yip L, Hickey V, Wagner B, et al. Skin prick test reactivity to recombinant latex allergens. Int Arch Allergy Immunol 2000; 121:292-299.
61. Vrtala S, Hirtenlehner K, Susani M, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-2047.
62. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101 (Suppl. 2):14677-14682.
63. Mahler V, Vrtala S, Kuss O, et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 2004; 34:115-122.
64. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106:124-134.
65. Ibarrola I, Sanz ML, Gamboa PM, et al. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 2004; 34:303-309.
66. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11 (4 Suppl.):S69-S76.
67. Slater JE, Paupore EJ, O'Hehir RE. Murine B-cell and T-cell epitopes of the allergen Hev b 5 from natural rubber latex. Mol Immunol 1999; 36:135-143.
68. Eusebius NP, Papalia L, Suphioglu C, et al. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (Bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol 2002; 127:234-244.
69. Hardy CL, Kenins L, Drew AC, et al. Characterization of a mouse model of allergy to a major occupational latex glove allergen Hev b 5. Am J Respir Crit Care Med 2003; 167:1393-1399.